



# Merseyside Inter Agency Drug Misuse Database

**Liverpool DAAT** 

Quarter 4 2007/08

Lloyd Baron, Martin Chandler, Jim McVeigh

www.cph.org.uk/iad

Acknowledgements:

The Authors would like to thank the following for their valuable contributions to the production of this report: Paul Duffy, Adam Marr, Simon Russell and Claire Shaw. We would also like to thank the data providers for their efforts in assisting and maintaining the monitoring process.

Contacts: Martin Chandler IAD Manager Centre for Public Health Faculty of Health & Applied Social Sciences Liverpool John Moores University Castle House North Street L3 2AY

(0151) 231 4531 m.chandler@ljmu.ac.uk

Lloyd Baron IAD Researcher

(0151) 231 4521 L.R.Baron@ljmu.ac.uk

www.cph.org.uk/iad

# Contents

Introduction		P <u>age</u> 1
Arrest Referral		3
	Table 1: Individuals assessed, by Gender	
	and Age Group	
	Table 2: Year to Date, by Gender and Age Group	
	Table 3: Reported Main Drug(s) of Use, by Frequency of Use	
Syringe Exchange	Services	5
Agenc	y .	
-	Table 4: Individuals by Gender	
	Table 5: Individuals by Gender: Steroid Users omitted	
	Table 6: Individuals by Age Group	
	Table 7: Individuals by Age Group: Steroid Users omitted	
	Table 8: Gender by Age Group of Individuals	
	Table 9: Gender by Age Group: Steroid Users omitted	
	Table 10: Year to Date, by Gender & Age Group	
	Table 11: Year to Date, by Gender & Age Group: Steroid Users	
	omitted	
	Table 12: Main Drug of Use for New Agency Syringe Exchange Clients, by Gender	
	Table 13: Main Drug of Use, for New Agency Syringe Exchange	<b>`</b>
	Clients, by Age Group	•
Pharm		10
	Table 14: Individuals by Gender	
	Table 15: Individuals by Age Group	
	Table 16: Year to Date, by Gender & Age Group	
Combi	ined	11
	Table 17: Individuals in Syringe Exchange, by Gender	
	Table 18: Individuals in Syringe Exchange, by Gender: Steroid I omitted	Jsers
	Table 19: Individuals in Syringe Exchange, by Age Group	
	Table 20: Individuals in Syringe Exchange, by Age Group: Stere	bid
	Users omitted	
	Table 21: Year to Date, by Gender & Age Group	
	Table 22: Total Syringes Provided	

National Drug Trea	atment Monitoring System (NDTMS)	13
	Table 23: Individuals in contact with Treatment Services, by Gende	ər
	Table 24: Year to Date, by Gender	
	Table 25: Individuals in contact with Treatment Services, by Age	
	Group	
	Table 26: Year to Date, by Age Group	
	Table 27: Ethnicity of Individuals in Contact with Treatment Service	es
	Table 28: Individuals in contact with Treatment Services, by Main	
	Drug of Use	
Connexions		16
	Table 29: Individuals in Contact with Connexions, by Gender	
	Table 30: Year to Date, by Gender	
	Table 31: Individuals in Contact with Connexions, by Age	
	Table 32: Year to Date, by Age	
	Table 33: Individuals in Contact with Connexions by Drug/Alcohol	
	Problem	
	Table 34: Year to Date, by Drug/Alcohol Problem	

#### **Combined Datasets**

Table 35: Total Problem Drug Users reported to the IAD, by Gender and Age Group Table 36: Year to Date, by Gender & Age Group 18

19

## **Cross Matched Datasets**

Fig 1: Crossover between Agency Syringe Exchange and NDTMS datasets Fig 2: Crossover between Pharmacy Syringe Exchange and NDTMS datasets

# Introduction

The Inter Agency Drug Misuse Database (IAD), established by Merseyside Drug (and Alcohol) Action Teams, Merseyside Police and the Public Health Sector (now Centre for Public Health) in 1997, supports the need for local information on drug misuse. In particular the IAD aims to:

- Provide comprehensive reporting of problem drug users' (PDUs') characteristics including a range of demographics and the types of drugs used.
- Reflect levels of service and intervention activity.
- Assist in D(A)AT's (and other responsible bodies) performance management.
- Facilitate the planning and development of services and interventions for PDUs.
- Identify gaps in service provision and delivery, as well as under-served groups as specified by the National Treatment Agency and Department of Health and by the Centre for Public Health, through interrogation of available data.
- Highlight changes in levels, demographics and characteristics of drug user populations.
- Report back to both individual D(A)ATs and service providers in the form of audits and quarterly reports as well as responding to ad hoc requests.
- Provide summary reporting on an annual basis.

To enable the above the IAD collects data from as many agencies in contact with drug users as possible and is continually seeking to expand the range and scope of data providers. Data are currently collected from criminal justice services, needle exchange schemes (both pharmacy and agency-based), the National Drug Treatment Monitoring System (NDTMS) and Connexions (young people).

#### **Data considerations**

Analysis of data depends on the provision of attributable information. Each service provider records first and last initials, date of birth and gender, for each individual they record a contact with. The combination of these details provides an identifier (attributor) for each individual (e.g.: HF07/12/1974M). This is a nationally recognised system and allows individuals to be tracked through different service providers and across time whilst retaining an acceptable degree of anonymity. The attributor is essential to avoid double counting of individuals both within and across datasets, as well as enabling us to match across datasets. The D(A)AT referred to is the D(A)AT of contact unless otherwise stated.

The IAD will *only* be reporting attributable data for each dataset. In the past, report deadlines have been missed due to data arriving too late to be cleaned and analysed in time, or more often because the data requires a great deal of cleaning and validation before analysis. These reports are useful only if they can arrive within timelines useful to D(A)ATs (ie: in time for NTA quarterly submissions). For this reason, reports will now be sent out according to a strict timetable, with each quarter's report to be sent in the first week of the third month following the close of the reporting period. Any data that is missing or non-attributable will not be included in the report.

Year-to-Date figures will be provided for the current financial year, and will incorporate updated figures from previous quarters. The figures are calculated by aggregating successive quarterly datasets to omit double counting of those who present to services in each quarter. Year-to-Date data will be the most accurate reflection of annual service activity and will override previous quarterly data.

The Centre for Public Health will continue to work closely with service providers and D(A)ATs in order to improve both the timeliness and quality of monitoring data provided to the IAD. Many service providers are turning to electronic recording of data and it is hoped this will vastly improve the quality of the data as systems improve.

# **ARREST REFERRAL (AR)**

Quarter 4 (2007/08)

#### Introduction

Raw data are provided by the Drug Intervention Programme (DIP) Team based at the Centre for Public Health, Liverpool John Moores University. The data supplied are for validated contacts within specified D(A)AT areas and are aggregated to one person per D(A)AT area. Individuals may therefore appear more than once within the final dataset if they have been seen in more than one D(A)AT area, but only once for each D(A)AT area within the reporting period.

Gender	n	%
Male	400	78.4
Female	110	21.6
Age Group		
Under 18	0	0.0
18-19	36	7.1
20-24	71	13.9
25-29	85	16.7
30-34	103	20.2
35-39	115	22.5
40-44	68	13.3
45+	32	6.3
Total	510	100

#### Table 1: Individuals assessed, by Gender & Age Group

Table 2: Year to Date, by Gender & Age Group

		Gei	nder			
	M	ale	Fen	nale	Total in A	ge Group
Age Group	n	%	n	%	n	%
Under 18	2	>1	0	0.0	2	>1
18-19	125	8.8	14	3.9	139	7.8
20-24	252	17.7	48	13.4	300	16.8
25-29	231	16.2	63	17.6	294	16.5
30-34	271	19.0	80	22.4	351	19.7
35-39	266	18.6	70	19.6	336	18.8
40-44	179	12.5	56	15.7	235	13.2
45+	101	7.1	26	7.3	127	7.1
Total	1427	100	357	100	1784	100

Drug of Use	Daily	Weekly
Amphetamines	0	1
Benzodiazepines	4	10
Cannabis	63	19
Crack	166	61
Cocaine	28	87
Ecstasy	2	1
Heroin	200	49
Methadone	10	5
Other	1	1

#### Table 3: Reported Main Drug(s) of Use, by Frequency of Use

**NB:** The complexity of the drug profiles reported through arrest referral is such that we have decided the best way of reporting the data is to provide figures for the number of people reporting Daily or Weekly use of each drug. Where "Main drug" is provided in the original data it does not always match the other substances reported as being used daily; consequently, this method of reporting should provide a more accurate picture of drug use as reported through Arrest Referral rather than simply stating the "Main Drug". However it should be noted that some people may report several drugs being used and will therefore be counted in the figures for each drug they report. For this reason totals are not provided.

# SYRINGE EXCHANGE SERVICES

Quarter 4 (2007/08)

#### Introduction

Data are collected directly from syringe exchange providers. Analysis of syringe exchange data allows performance monitoring of harm reduction services at both D(A)AT and service provider level.

#### AGENCY SYRINGE EXCHANGE

#### Table 4: Individuals by Gender

New Clients	n	%
Male	140	83.8
Female	27	16.2
Total	167	100
All Clients		
Male	419	90.1
Female	46	9.9
Total	465	100

#### Table 5: Individuals by Gender: Steroids Users Omitted

New Clients	n	%
Male	70	72.9
Female	26	27.1
Total	96	100
All Clients		
Male	216	82.8
Female	45	17.2
Total	261	100

	New	Clients	All C	lients
Age Group	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	4	2.4	8	1.7
20-24	24	14.4	51	11.0
25-29	29	17.4	77	16.6
30-34	26	15.6	86	18.5
35-39	47	28.1	122	26.2
40-44	24	14.4	72	15.5
45+	13	7.8	49 10.5	
Total	167	100	465	100

# Table 6: Individuals by Age Group

## Table 7: Individuals by Age Group: Steroid Users omitted

	New	Clients	All C	lients
Age Group	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	2	2.1	2	>1
20-24	4	4.2	4	1.5
25-29	7	7.3	22	8.4
30-34	17	17.7	52	19.9
35-39	35	36.5	89	34.1
40-44	19	19.8	52	19.9
45+	12	12.5	40	15.3
Total	96	100	261	100

		Ge	nder	
	N	lale	Fei	male
Age Group	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	8	1.9	0	0.0
20-24	51	12.2	0	0.0
25-29	71	16.9	6	13.0
30-34	73	17.4	13	28.3
35-39	109	26.0	13	28.3
40-44	66	15.8	6	13.0
45+	41	9.8	8	17.4
Total	419	100	46	100

# Table 8: Gender by Age Group of Individuals

# Table 9: Gender by Age Group: Steroid Users omitted

		Ge	nder	
	М	ale	Fei	male
Age Group	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	2	>1	0	0.0
20-24	4	1.9	0	0.0
25-29	16	7.4	6	13.3
30-34	40	18.5	12	26.7
35-39	76	35.2	13	28.9
40-44	46	21.3	6	13.3
45+	32	14.8	8	17.8
Total	216	100	45	100

		Gei	nder			
Age Group	M	ale	Female		Total in Age Group	
	n	%	n	%	n	%
Under 18	2	<1	0	0.0	2	<1
18-19	22	2.2	1	<1	23	2.0
20-24	122	12.1	4	3.4	126	11.2
25-29	197	19.5	22	18.6	219	19.4
30-34	174	17.2	27	22.9	201	17.8
35-39	250	24.8	26	22.0	276	24.5
40-44	147	14.6	26	22.0	173	15.4
45+	95	9.4	12	10.2	107	9.5
Total	1009	100	118	100	1127	100

# Table 10: Year to Date, by Gender & Age Group

## Table 11: Year to Date, by Gender & Age Group: Steroid Users Omitted

		Gei	nder			
	M	Male		nale	Total in Age Group	
Age Group	n	%	n	%	n	%
Under 18	2	<1	0	0.0	2	<1
18-19	5	1.0	1	<1	6	1.0
20-24	14	2.7	4	3.5	18	2.9
25-29	45	8.8	21	18.3	66	10.6
30-34	87	17.1	26	22.6	113	18.1
35-39	181	35.5	25	21.7	206	33.0
40-44	109	21.4	26	22.6	135	21.6
45+	67	13.1	12	10.4	79	12.6
Total	510	100	115	100	625	100

	N	lale	Fen	nale
Drug of Use	n	%	n	%
Amphetamines	0	0.0	0	0.0
Benzodiazepines	0	0.0	0	0.0
Cocaine	0	0.0	1	3.7
Crack	2	1.4	0	0.0
Heroin	63	45.0	22	81.5
Methadone	1	>1	0	0.0
Steroids	70	50.0	1	3.7
Other	4	3.00	3	11.1
Total	140	100	27	100

# Table 12: Main Drug of Use for New Agency Syringe Exchange Clients, by Gender

Please Note: Due to changes in reporting methods we will now only report drug of use for new clients. Information on drug of use for all clients is available on request.

Table 13: Main Drug of	Use for New	Agency Syringe	Exchange Client	s, by Age Group

		heta- ne		zodi- pine	Coc	aine	Cr	ack	He	roin	Metha	adone	Stei	roids
Age Group	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Under 18	-	-	-	-	-	-	-	-	-	-	-	-	-	-
18-19	-	-	-	-	-	-	-	-	-	-	-	-	2	3.0
20-24	-	-	-	-	-	-	-	-	4	5.0	-	-	20	28.0
25-29	-	-	-	-	-	-	-	-	7	8.0	-	-	22	31.0
30-34	-	-	-	-	-	-	-	-	15	18.0	-	-	9	13.0
35-39	-	-	-	-	-	-	1	50.0	32	38.0	-	-	12	17.0
40-44	-	-	-	-	-	-	1	50.0	18	21.0	-	-	5	7.0
45+	-	-	-	-	1	100	-	-	9	11.0	1	100	1	1.0
Total*	-	-	-	-	1	100	2	100	85	100	1	100	71	100

\* % Totals are by Drug, not Age Group

# PHARMACY SYRINGE EXCHANGE

#### Table 14: Individuals by Gender

New Clients	n	%
Male	801	82.5
Female	170	17.5
Total	971	100
All Clients		
Male	1266	82.4
Female	271	17.6
Total	1537	100

# Table 15: Individuals by Age Group

	New	Clients	All Clients		
Age Group	n	%	n	%	
Under 18	2	>1	2	>1	
18-19	20	2.1	27	1.8	
20-24	106	10.9	148	9.6	
25-29	155	16.0	213	13.9	
30-34	160	16.5	269	17.5	
35-39	253	26.1	433	28.2	
40-44	182	18.7	294	19.1	
45+	93	9.6	151	9.8	
Total	971	100	1537	100	

# Table 16: Year to Date, by Gender & Age Group

		Ger	nder			
	Ma	ale	Fen	nale	Total in Age Group	
Age Group	n	%	n	%	n	%
Under 18	5	>1	2	>1	7	>1
18-19	56	2.1	6	1.0	62	1.9
20-24	294	10.8	47	8.0	341	10.3
25-29	380	14.0	94	16.0	474	14.3
30-34	471	17.3	107	18.2	578	17.5
35-39	743	27.3	171	29.0	914	27.6
40-44	512	18.8	96	16.3	608	18.4
45+	257	9.5	66	11.2	323	9.8
Total	2718	100	589	100	3307	100

# COMBINED PHARMACY AND AGENCY SYRINGE EXCHANGE

Analyses here are based on an aggregated combination of Agency and Pharmacy-based datasets for the reporting period. Data are aggregated by attributor and D(A)AT to one person per D(A)AT area.

New Clients	n	%	
Male	916	82.6	
Female	193	17.4	
Total	1109	100	
All Clients			
Male	1613	84.1	
Female	306	15.9	
Total	1919	100	

Table 17: Individuals in Syringe Exchange, by Gender

#### Table 18: Individuals in Syringe Exchange, by Gender: Steroid Users Omitted\*

New Clients	n	%	
Male	837	81.5	
Female	190	18.5	
Total	1027	100	
All Clients			
Male	1398	82.2	
Female	303	17.8	
Total	1701	100	

\*Only known steroid users, based on Agency SES data, have been omitted.

Table 19: Individuals in Syringe Exchange, by Age Group

	New	Clients	All C	lients
Age Group	n	%	n	%
Under 18	2	>1	2	>1
18-19	24	2.2	35	1.8
20-24	129	11.6	197	10.3
25-29	179	16.1	279	14.5
30-34	178	16.1	339	17.7
35-39	296	26.7	523	27.3
40-44	199	17.9	353	18.4
45+	102	9.2	191	10.0
Total	1109	100	1919	100

	New	Clients	All C	lients
Age Group	n	%	n	%
Under 18	2	>1	2	>1
18-19	21	2.0	27	1.6
20-24	106	10.3	147	8.6
25-29	155	15.1	221	13.0
30-34	169	16.5	304	17.9
35-39	280	27.3	486	28.6
40-44	193	18.8	332	19.5
45+	101	9.8	182	10.7
Total	1027	100	1701	100

## Table 20: Individuals in Syringe Exchange by Age Group: Steroid Users Omitted

#### Table 21: Year to Date, by Gender & Age Group

		Gei	nder			
	M	ale	Fen	nale	Total in Age Group	
Age Group	n	%	n	%	n	%
Under 18	7	>1	2	>1	9	>1
18-19	78	2.2	6	>1	84	2.0
20-24	408	11.7	50	7.6	458	11.0
25-29	548	15.7	109	16.6	657	15.9
30-34	601	17.2	120	18.2	721	17.4
35-39	901	25.8	182	27.7	1083	26.1
40-44	616	17.7	114	17.3	730	17.6
45+	328	9.4	75	11.4	403	9.7
Total	3487	100	658	100	4145	100

#### Table 22: Total Syringes Provided

	Agency	Pharmacy	Total (Q)	Year to Date
Barrels	15,838	132,486	148,324	456,206

**NB:** We will no longer be reporting needle returns as it is not possible to accurately calculate them from the data available. Total Syringes include exchanges by non-attributable individuals.

# National Drug Treatment Monitoring System (NDTMS) Quarter 4 (2007/08)

#### Background

The NDTMS is the official method for measuring the extent and nature of structured drug treatment in England and Wales. The system is commissioned by the NTA and is operated through nine regional centres – corresponding to the nine government offices for the regions.

Data here are aggregated to one individual per D(A)AT. Individuals presenting in more than one D(A)AT within the quarter's time period will therefore be represented more than once in the original data. The D(A)AT referred to is D(A)AT of treatment.

#### **New Clients**

Figures presented here for "new" clients are calculated using the triage date. Those individuals triaged within the reporting period are taken as new clients for this report. However, it should be noted that these individuals may have been triaged, or in contact with treatment services, before this period.

New Clients	n	%
Male	485	72.4
Female	185	27.6
Total	670	100
All Clients		
Male	3125	70.5
Female	1305	29.5
Total	4430	100

#### Table 23: Individuals in Contact with Treatment Services, by Gender

#### Table 24: Year to Date, by Gender

New Clients	n	%
Male	1568	72.4
Female	599	27.6
Total	2167	100
All Clients		
Male	3335	70.4
Female	1401	29.6
Total	4736	100

	New Clients		All C	lients
Age Group	n	%	n	%
Under 18	41	6.1	176	3.9
18-19	14	2.1	100	2.3
20-24	38	5.6	203	4.5
25-29	70	10.4	408	9.2
30-34	139	20.7	705	15.9
35-39	160	23.8	1153	26.
40-44	121	18.0	1017	22.9
45+	87	12.9	668	15.1
Total	670	100	4430	100

# Table 25: Individuals in Contact with Treatment Services, by Age Group

## Table 26: Year to Date, by Age Group

	New	Clients	All C	lients
Age Group	n	%	n	%
Under 18	133	6.2	233	4.9
18-19	53	2.4	89	1.9
20-24	148	6.8	303	6.4
25-29	273	12.6	547	11.5
30-34	448	20.7	993	21.0
35-39	508	23.4	1268	26.8
40-44	380	17.6	816	17.2
45+	224	10.3	487	10.3
Total	2167	100	4736	100

	New (	Clients	All Cl	ients
Ethnicity	n	%	n	%
White British	629	93.8	4054	91.5
White Irish	8	1.1	27	>1
Other White	2	>1	45	1.
White & Black Caribbean	7	1.0	19	>1
White & Black African	0	0.0	8	>1
White & Asian	0	0.0	6	>1
Other Mixed	2	>1	17	>1
Other Asian	2	>1	10	>1
Caribbean	2	>1	9	>1
African	1	>1	10	>1
Other Black	7	1.0	54	1.2
Chinese	1	>1	8	>1
Other	1	>1	23	>1
Unknown	8	1.2	140	3.0
Total	670	100	4430	100

# Table 27: Ethnicity of Individuals in Contact with Treatment Services

# Table 28: Individuals in Contact with Treatment Services, by Main Drug of Use

	New (	Clients	All C	lients
Drug of Use	n	%	n	%
Heroin	427	63.7	2893	65.3
Methadone	37	5.5	310	7.0
Other Opiates	7	1.0	34	>1
Benzodiazepine	0	0.0	11	>1
Amphetamines	7	1.0	30	>1
Cocaine	89	13.2	529	11.9
Crack	25	3.7	156	3.5
Ecstasy	0	0.0	13	>1
Cannabis	74	11.0	355	8.0
Other/Unknown	4	>1	99	2.0
Total	670	100	4430	100

# **CONNEXIONS**

Quarter 4 (2007/08)

# Background

Connexions provide a support service for young people, aged 13-19. The Greater Merseyside Connexions Partnership provides data presented here.

#### Table 29: Individuals in Contact with Connexions, by Gender

Gender	n	%
Male	79	67.5
Female	38	32.5
Total	117	100

#### Table 30: Year to Date, by Gender

Gender	n	%
Male	126	67.7
Female	60	32.3
Total	186	100

Table 31: Individuals in Contact with Connexions, by Age

Age Group	n	%
16	37	31.6
17	36	30.8
18	26	22.2
19	18	15.4
Total	117	100

#### Table 32: Year to Date, by Age

Age Group	n	%
16	47	25.3
17	54	29.0
18	44	23.7
19	41	22.0
Total	186	100

Substance	n	%
Alcohol/Other*	29	24.8
Drugs	88	75.2
Total	117	100

## Table 33: Individuals in Contact with Connexions by Drug/Alcohol Problem

\*"Other" is generally used to refer to solvents although this is not necessarily always the case.

#### Table 34: Year to Date, by Drug/Alcohol Problem

Substance	n	% 23.1 76.9	
Alcohol/Other*	43		
Drugs	143		
Total	186	100	

\*"Other" is generally used to refer to solvents although this is not necessarily always the case.

# COMBINED DATASETS Quarter 4 (2007/08)

#### Introduction

Data presented here are drawn from a combination of datasets relating to Arrest Referrals, Probation, Syringe Exchange (Agency and Pharmacy), NDTMS and Connexions. The combined data are aggregated on attributor and D(A)AT area of intervention (except Probation, which is based on residence), to produce overall figures for numbers of individuals in contact with services reporting to the IAD. Figures presented here will not necessarily reflect the combined totals of data presented earlier as duplicate attributors are removed. These figures should not be taken as a measure of prevalence of problem drug users, but reflects the total number of problem drug users in contact with a range of agencies. Further information on the processes of data manipulation, aggregation and analysis is available from the IAD Manager.

Gender	n	%	
Male	4706	74.5	
Female	1613	25.5	
Age Group			
Under 18	294	4.7	
18-19	190	3.0	
20-24	522	8.3	
25-29	800	12.7	
30-34	1215	19.2	
35-39	1588	25.1	
40-44	1085	17.2	
45+	625	9.9	
Total	6319	100	

#### Table 35: Total Problem Drug Users reported to the IAD, by Gender and Age Group

#### Table 36: Year to Date, by Gender and Age Group

	Gender					
Age Group	Male		Female		Total in Age Group	
	n	%	n	%	n	%
Under 18	231	3.1	72	3.4	303	3.2
18-19	349	4.7	65	3.0	414	4.3
20-24	847	11.4	152	7.1	999	10.4
25-29	1010	13.5	287	13.5	1297	13.5
30-34	1167	15.6	388	18.2	1555	16.2
35-39	1700	22.8	547	25.7	2247	23.4
40-44	1326	17.8	384	18.0	1710	17.8
45+	831	11.1	237	11.1	1068	11.1
Total	7461	100	2132	100	9593	100

# CROSS-MATCHED DATASETS Quarter 4 (2007/08)

Data are shown for the crossover between each type of Syringe Exchange and NDTMS, separately, during the current reported quarter. For the purposes of this analysis, known steroid users were removed as they are less likely to be accessing structured drug treatment.

For methodological reasons the crossover between all three datasets will no longer be reported. Further information is available from the IAD manager if required.

NB: Numbers in brackets refer to the total reported for that service type, with steroid users omitted. These include the numbers appearing on the crossover sections. Analyses for the crossover areas are based on D(A)AT of Syringe Exchange site.




Fig 1: Crossover between Agency Syringe Exchange and NDTMS datasets

Fig 2: Crossover between Pharmacy Syringe Exchange and NDTMS datasets

